Jim Daly left his post as head of North America commercial operations for Amgen to join biotech firm Incyte in the role of EVP and chief commercial officer. He arrives a year into the launch of Incyte's Jakafi, the first drug specifically approved for myelofibrosis, a rare, life-threatening blood cancer. Jakafi was also the first FDA-approved JAK inhibitor, a class that includes Pfizer's experimental rheumatoid arthritis pill tofacitinib.
James Sapirstein assumed the CEO position at Alliqua, a New York-based firm that produces and markets a transdermal drug delivery platform for wound care. A pharma veteran with more than 20 years of experience, Sapirstein has held several executive roles in the industry, most recently as CEO of privately held Tobira Therapeutics and as EVP at Serono Labs. A pharmacist by training, he began his career as a sales rep at Roche. After a decade there, Sapirstein moved to Bristol-Myers Squibb, rising to director of international marketing for infectious diseases, then spent several years in global marketing at Gilead Sciences.